WuXi AppTec (HKG:2359, SHA:603259) disposed of a further 50.8 million shares, equivalent to a 4.23% stake, in WuXi XDC Cayman (HKG:2268) for around HK$2.18 billion on Tuesday, a Wednesday filing with the Hong Kong bourse said.
The drug research and development company previously sold 86 million shares in the target company for roughly HK$2.43 billion on Nov. 8, 2024, and Jan. 10, 2025.
The firm will use proceeds from the sale to accelerate the construction of global production capacity and capability, attract and retain outstanding talent, and strengthen its unique integrated CRDMO business model.